A detailed history of Tekla Capital Management LLC transactions in Chinook Therapeutics, Inc. stock. As of the latest transaction made, Tekla Capital Management LLC holds 150,863 shares of KDNY stock, worth $0. This represents 0.23% of its overall portfolio holdings.

Number of Shares
150,863
Previous 83,500 80.67%
Holding current value
$0
Previous $1.93 Million 199.84%
% of portfolio
0.23%
Previous 0.07%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 10, 2023

BUY
$18.66 - $38.58 $1.26 Million - $2.6 Million
67,363 Added 80.67%
150,863 $5.8 Million
Q1 2023

May 10, 2023

BUY
$21.53 - $26.8 $1.8 Million - $2.24 Million
83,500 New
83,500 $1.93 Million

Others Institutions Holding KDNY

About CHINOOK THERAPEUTICS, INC.


  • Ticker KDNY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 62,896,300
  • Description
  • Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...
More about KDNY
Track This Portfolio

Track Tekla Capital Management LLC Portfolio

Follow Tekla Capital Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tekla Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Tekla Capital Management LLC with notifications on news.